Screening of potential prodrugs on cells derived from Dupuytren's disease patients

Biomedicine and Pharmacotherapy

Volumn 63, Issue 8, 2009, Pages 577-585

  Kraljevic Pavelic, Sandra ^a   Bratulic, Sinisa ^a   Hock, Karlo ^a   Jurisic, Davor ^b   Hranjec, Marijana ^c   Karminski Zamola, Grace ^c   Zinic, Biserka ^a   Bujak, Maro ^a   Pavelic, Kresimir ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b KBC RIJEKA   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Dupuytren's contracture; Fibroblasts; Myofibroblasts

Indexed keywords

AMIDINODIHYDROTHIENOTHIENYL[2,3 C]QUINOLONE; BENZIMIDAZO[1,2 A]QUINOLINE; CYTOSTATIC AGENT; FLUOROURACIL; N SULFONYLPYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSKELETON; DRUG SCREENING; DRUG SPECIFICITY; DUPUYTREN CONTRACTURE; FIBROBLAST CULTURE; HAND SURGERY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MYOFIBROBLAST; PALMAR FASCIA; PRIORITY JOURNAL; RECURRENCE RISK;

CASE-CONTROL STUDIES; CELL CYCLE; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DUPUYTREN CONTRACTURE; FASCIA; FIBROBLASTS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MIDDLE AGED; MOLECULAR STRUCTURE; PRODRUGS; PYRIMIDINES; QUINOLINES; QUINOLONES; RECURRENCE; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 70349337880     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2008.10.005     Document Type: Article

References (36)

1. Bulstrode N.W., Bisson M., Jemec B., Pratt A.L., McGrouther D.A., and Grobbelaar A.O. A prospective randomised clinical trial of the intra-operative use of 5-fluorouracil on the outcome of Dupuytren's disease. J Hand Surg-Br Eur 29B (2004) 18-21
2. Badalamente M.A., Hurst L.C., and Hentz V.R. Collagen as a clinical target: nonoperative treatment of Dupuytren's disease. J Hand Surg [Am] 27A (2002) 788-798
3. Bulstrode N.W., Mudera V., McGrouther D.A., Grobbelaar A.O., and Cambrey A.D. 5-Fluorouracil selectively inhibits collagen synthesis. Plast Reconstr Surg 116 (2005) 209-221
4. Bisson M.A., McGrouther D.A., Mudera V., and Grobbelaar A.O. The different characteristics of Dupuytren's disease fibroblasts derived from either nodule or cord: expression of alpha-smooth muscle actin and the response, to stimulation by TGF-beta(1). J Hand Surg-Br Eur 28B (2003) 351-356
5. Shephard P., Martin G., Smola-Hess S., Brunner G., Krieg T., and Smola H. Myofibroblast differentiation is induced in keratinocyte-fibroblast co-cultures and is antagonistically regulated by endogenous transforming growth factor-beta and interleukin-1. Am J Pathol 164 (2004) 2055-2066
6. Cordova A., Tripoli M., Corradino B., Napoli P., and Moschella F. Dupuytren's contracture: an update of biomolecular aspects and therapeutic perspectives. J Hand Surg-Br Eur 30B (2005) 557-562
7. Mason J.M., Xu H.P., Rao S.K., Leask A., Barcia M., Shan J.D., et al. Lefty contributes to the remodeling of extracellular matrix by inhibition of connective tissue growth factor and collagen mRNA expression and increased proteolytic activity in a fibrosarcoma model. J Biol Chem 277 (2002) 407-415
8. Hurst L.C., and Badalamente M.A. Nonoperative treatment of Dupuytren's disease. Hand Clin 15 (1999) 97-107
9. Rayan G.M., Parizi M., and Tomasek J.J. Pharmacologic regulation of Dupuytren's fibroblast contraction in vitro. J Hand Surg [Am] 21A (1996) 1065-1070
10. Badalamente M.A., and Hurst L.C. Enzyme injection as nonsurgical treatment of Dupuytren's disease. J Hand Surg [Am] 25A (2000) 629-636
11. Jemec B., Linge C., Grobbelaar A.O., Smith P.J., Sanders R., and McGrouther D.A. The effect of 5-fluorouracil on Dupuytren fibroblast proliferation and differentiation. Chir Main 19 (2000) 15-22
12. Kuhn M.A., Wang X., Payne W.G., Ko F., and Robson M.C. Tamoxifen decreases fibroblast function and downregulates TGF(beta2) in Dupuytren's affected palmar fascia. J Surg Res 103 (2002) 146-152
13. Namazi H. Imiquimod: a potential weapon against Dupuytren contracture. Med Hypotheses 66 (2006) 991-992
14. Meek R.M.D., McLellan S., Reilly J., and Crossan J.F. The effect of steroids on Dupuytren's disease: role of programmed cell death. J Hand Surg-Br Eur 27B (2002) 270-273
15. Wong M., and Mudera V. Feedback inhibition of high TGF-beta 1 concentrations on myofibroblast induction and contraction by Dupuytren's fibroblasts. J Hand Surg-Br Eur 31B (2006) 473-483
16. Zinic B., Krizmanic I., Glavas-Obrovac L., Karner I., and Zinic M. Synthesis and antitumor activity of N-sulfonyl derivatives of nucleobases and sulfonamido nucleoside derivatives. Nucleosides Nucleotides Nucleic Acids 22 (2003) 1623-1625
17. Gazivoda T., Plevnik M., Plavec J., Kraljevic S., Kralj M., Pavelic K., et al. The novel pyrimidine and purine derivatives of l-ascorbic acid: synthesis, one- and two-dimensional H-1 and C-13 NMR study, cytostatic and antiviral evaluation. Bioorg Med Chem 13 (2005) 131-139
18. Opacic N., Barbaric M., Zorc B., Cetina M., Nagy A., Frkovic D., et al. The novel l- and d-amino acid derivatives of hydroxyurea and hydantoins: synthesis, X-ray crystal structure study, and cytostatic and antiviral activity evaluations. J Med Chem 48 (2005) 475-482
19. Jarak I., Kralj M., Piantanida I., Suman L., Zinic M., Pavelic K., et al. Novel cyano- and amidino-substituted derivatives of thieno[2,3-b]- and thieno[3,2-b]thiophene-2-carboxanilides and thieno[3′,2′: 4,5]thieno- and thieno[2′,3′: 4,5]thieno [2,3-c]quinolones: synthesis, photochemical synthesis, DNA binding, and antitumor evaluation. Bioorg Med Chem 14 (2006) 2859-2868
20. Hranjec M., Kralj M., Piantanida I., Sedic M., Suman L., Pavelic K., et al. Novel cyano- and amidino-substituted derivatives of styryl-2-benzimidazoles and benzimidazo[1,2-a]quinolones. Synthesis, photochemical synthesis, DNA binding and antitumor evaluation. J Med Chem 50 (2007) 5696-5711
21. Rayan G.M. Dupuytren disease: anatomy, pathology, presentation, and treatment. J Bone Joint Surg Am 89A (2007) 190-198
22. Roninson I.B. Oncogenic functions of tumour suppressor p21 (Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett 179 (2002) 1-14
23. Liu S.X., Bishop W.R., and Liu M. Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updat 6 (2003) 183-195 [Review]
24. Andrew J.G., Andrew S.M., Ash A., and Turner B. An investigation into the role of inflammatory cells in Dupuytren's disease. J Hand Surg-Br Eur 16 (1991) 267-271
25. Baird K.S., Alwan W.H., Crossan J.F., and Wojciak B. T-cell-mediated response in Dupuytren's disease. Lancet 341 (1993) 1622-1623
26. Um H.D., Orenstein J.M., and Wahl S.M. Fas mediates apoptosis in human monocytes by a reactive oxygen intermediate dependent pathway. J Immunol 156 (1996) 3469-3477
27. Fitzgerald A.M., Kirkpatrick J.J., and Naylor I.L. Dupuytren's disease. The way forward?. J Hand Surg-Br Eur 24 (1999) 395-399
28. Glavas-Obrovac L., Karner I., Zinic B., and Pavelic K. Antineoplastic activity of novel N-1-sulfonypyrimidine derivatives. Anticancer Res 21 (2001) 1979-1986
29. Tomasek J.J., Gabbiani G., Hinz B., Chaponnier C., and Brown R.A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 3 (2002) 349-363 [Review]
30. Hindman H.B., Marty-Roix R., Tang J.B., Jupiter J.B., Simmons B.P., and Spector M. Regulation of expression of alpha-smooth muscle actin in cells of Dupuytren's contracture. J Bone Joint Surg Br 85 (2003) 448-455
31. Chang B.D., Watanabe K., Broude E.V., Fang J., Poole J.C., Kalinichenko T.V., et al. Effects of p21(Waf1/Cip1/Sdi1) on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc Natl Acad Sci U S A 97 (2000) 4291-4296
32. Bayat A., Watson J.S., Stanley J.K., Alansari A., Shah M., Ferguson M.W.J., et al. Genetic susceptibility in Dupuytren's disease - TGF-beta 1 polymorphisms and Dupuytren's disease. J Bone Joint Surg Br 84B (2002) 211-215
33. Prekupec S., Makuc D., Plavec J., Kraljevic S., Kralj M., Pavelic K., et al. Antiviral and cytostatic evaluation of the novel 6-acyclic chain substituted thymine derivatives. Antivir Chem Chemother 16 (2005) 327-338
34. Zinic B, Krizmanic I, Zinic M. Synthesis of the sulfonylpyrimidine derivatives with anticancer activity. EP 0 887 022 B1 (Bulletin 1003/16, 2003.)
35. Kasnar B., Krizmanic I., and Zinic M. Synthesis of the sulfonylpyrimidine derivatives as a new type of sulfonylcycloureas. Nucleosides Nucleotides 16 (1997) 1067-1071
36. Xia Y., Yang Z.Y., Hour M.J., Kuo S.C., Xia P., Bastow K.F., et al. Antitumor agents. Part 204: synthesis and biological evaluation of substituted 2-aryl quinazolinones. Bioorg Med Chem Lett 11 (2001) 1193-1196